Overview:

Conduct smarter hematological oncology R&D faster with SpecimenSeq

Bridging a deep understanding of molecular profiles with clinical information is critical to developing innovative precision medicine tools in oncology. SpecimenSeq makes this challenge easier for hematological oncology developers by delivering access to fully consented, ethically collected BMMCs and PBMCs characterized with the Illumina TruSight Myeloid Panel

Contact Our Biospecimens Team

SpecimenSeq™ Allows Companies to Accelerate:

Biomarker Discovery

Verification of the presence of biomarker targets in your populations of interest

Heme-Onc
Assessing Mutations

Confirmation of driver mutations and other clinically relevant genomic variants in viable BMMCs and PBMCs

Oncology Therapeutics

Acceleration of timelines for identifying responders versus non-responders and efficacy evaluations for new cancer therapies

Deliverables & Characterization:

BMMCs, PBMCs, and BMMCs + PBMCs Matched Sets
Biospecimen FormatCharacterization and Reports
BMMCs
  • Clinical information and pathology report
  • Qiagen’s Clinical Insights (QCI) pipeline report
  • Previous treatment information (if applicable)
  • Flow Cytometry characterization (if available)
PBMCs
  • Clinical information and pathology report
  • Qiagen’s Clinical Insights (QCI) pipeline report
  • Previous treatment information (if applicable)
BMMCs + PBMCs
  • Clinical information and pathology report
  • Qiagen’s Clinical Insights (QCI) pipeline report
  • Previous treatment information (if applicable)
  • Flow Cytometry characterization (if available)
NGS Characterization
TruSight Myeloid Sequencing Panel Gene List
ABL1CEBPAHRASMYD88SF3B1
ASXL1CSF3RIDH1NOTCH1SMC1A
ATRXCUX1IDH2NPM1SMC3
BCORDNMT3AIKZF1NRASSRSF2
BCORL1ETV6/TELJAK2PDGFRASTAG2
BRAFEZH2JAK3PHF6TET2
CALRFBXW7KDM6APTENTP53
CBLFLT3KITPTPN11U2AF1
CBLBGATA1KRASRAD21WT1
CBLCGATA2MLLRUNX1ZRSR2
CDKN2AGNASMPLSETBP1
NGS results are delivered via a Qiagen Clinical Insights (QCI) report that includes:
  • Genomic variants that have been shown to have clinical relevance
  • Pathogenicity and level of clinical significance according to clinical guidelines
  • Predicted protein changes
  • Relevant drug treatments or resistance to drugs based on the genetic variants
  • Relevant active clinical trials for patients that would harbor the same genomic variants as were identified in the biospecimen sample
Download a Sample Report
Additional characterizations are available through our expert, integrated service laboratories.
Cell Services
Learn More
IHC Services
Learn More

Submit Inventory Requests

Highlight your samples of interest and submit the saved inventory report file via the contact form below.